Why is Vertex stock sliding today?
Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.
How this was made
The 30-second read
Why it matters
Traders likely reprice the stock on the guidance gap and cash-flow deterioration, while weighing offsetting positives like margin expansion and higher full-year adjusted EBITDA guidance.
Market read
A guidance miss versus consensus and weaker free cash flow are the immediate catalysts behind a large single-day selloff despite a headline earnings beat.
What to watch
Free cash flow contraction is attributed to higher capex; if capex is tied to near-term growth investments, the market may be over-discounting the cash impact.
Background
The piece attributes today’s decline to a post-close Q2 2026 earnings report that beat on EPS and revenue but guided Q3 revenue below consensus, alongside a sharp free-cash-flow contraction.
Ticker impact
Vertex shares fell 12.8% after Q2 beat but Q3 revenue guidance midpoint ($209.5M) lagged consensus (~$211.69M) and free cash flow dropped to $2.7M.
Near-term downside risk remains elevated until investors get clearer evidence that revenue growth and free cash flow are stabilizing.
The article cites a specific guidance miss versus consensus, a sharp free-cash-flow contraction, and an overhang from a prior Morgan Stanley downgrade with a lower price target.
Market effects
Could pressure sentiment for similarly positioned biotech/healthcare growth names if investors broaden the read-across from guidance and cash-flow quality.
Limited, since the article frames the move as company-specific versus S&P 500 and Nasdaq strength.
Low, no cross-border catalysts or global policy/regulatory items are mentioned.
Counterpoint
The article notes improved adjusted EBITDA margin and raised full-year adjusted EBITDA guidance, which could support a rebound if investors refocus on profitability rather than near-term revenue pacing.
Key entities
- companyVertex
Subject of the article, with a 12.8% morning drop tied to Q3 revenue guidance below consensus and lower free cash flow.
- analyst_firmMorgan Stanley
Downgraded Vertex to Equal Weight from Overweight in late June and cut its price target to $15 from $19.
